A Phase IIIb Open-label run-in Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety/Efficacy of Certolizumab Pegol Administered Concomitantly With Stable-dose Methotrexate in Patients With Active Rheumatoid Arthritis.
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005136/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 patients will be grouped as responders or non-responders based on results of the ACR20 at Week 16.
提供机构：
Vivli
创建时间：
2020-01-15
